{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:19:35Z","timestamp":1793827175511,"version":"4.6.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40257-015-0162-4","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T18:31:10Z","timestamp":1449772270000},"page":"33-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review"],"prefix":"10.1007","volume":"17","author":[{"given":"Theresa N.","family":"Canavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Elmets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy L.","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni E.","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"162_CR1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512\u20136.","journal-title":"J Am Acad Dermatol."},{"key":"162_CR2","doi-asserted-by":"crossref","unstructured":"Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8). pii: 13030\/qt48r4w8h2.","DOI":"10.5070\/D3208023523"},{"key":"162_CR3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archderm.1969.01610300005001","volume":"100","author":"CJ McDonald","year":"1969","unstructured":"McDonald CJ, Bertino JR. Parenteral methotrexate in psoriasis: a report on the efficacy and toxicity of long-term intermittent treatment. Arch Dermatol. 1969;100:655\u201368.","journal-title":"Arch Dermatol."},{"key":"162_CR4","first-page":"408","volume":"111","author":"W M\u00fcller","year":"1981","unstructured":"M\u00fcller W, Graf U. The treatment of psoriasis-arthritis with cyclosporin A, a new immunosuppressive agent. Schweiz Med Wochenschr. 1981;111:408\u201313.","journal-title":"Schweiz Med Wochenschr."},{"key":"162_CR5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mjd.2001.117852","volume":"45","author":"A Martin","year":"2001","unstructured":"Martin A, Gutierrez E, Muglia J, McDonald CJ, Guzzo C, Gottlieb A, et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol. 2001;45:871\u201381.","journal-title":"J Am Acad Dermatol."},{"key":"162_CR6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1523-1747.ep12371679","volume":"101","author":"K Uyemura","year":"1993","unstructured":"Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101:701\u20135.","journal-title":"J Invest Dermatol."},{"key":"162_CR7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","volume":"25","author":"CT Weaver","year":"2007","unstructured":"Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821\u201352.","journal-title":"Annu Rev Immunol."},{"key":"162_CR8","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","volume":"129","author":"EG Harper","year":"2009","unstructured":"Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129:2175\u201383.","journal-title":"J Invest Dermatol."},{"key":"162_CR9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.intimp.2013.02.018","volume":"16","author":"Y Cai","year":"2013","unstructured":"Cai Y, Fleming C, Yan J. Dermal \u03b3\u03b4 T cells\u2013a new player in the pathogenesis of psoriasis. Int Immunopharmacol. 2013;16:388\u201391.","journal-title":"Int Immunopharmacol."},{"key":"162_CR10","unstructured":"Press Announcements\u2014FDA approves new psoriasis drug Cosentyx [Internet]. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm430969.htm . Cited 29 Mar 2015."},{"key":"162_CR11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, Ortonne J-P, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181\u20139.","journal-title":"N Engl J Med."},{"key":"162_CR12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412\u201321.","journal-title":"Br J Dermatol."},{"key":"162_CR13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","volume":"168","author":"P Rich","year":"2013","unstructured":"Rich P, Sigurgeirsson B, Thaci D, Ortonne J-P, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402\u201311.","journal-title":"Br J Dermatol."},{"key":"162_CR14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","volume":"28","author":"C Paul","year":"2014","unstructured":"Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol JEADV. 2014;28:1670\u20135.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"162_CR15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jdv.12343","volume":"28","author":"B Sigurgeirsson","year":"2014","unstructured":"Sigurgeirsson B, Kircik L, Nemoto O, Mikazans I, Haemmerle S, Thurston HJ, et al. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and\/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. J Eur Acad Dermatol Venereol JEADV. 2014;28:1127\u20139.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"162_CR16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","volume":"24","author":"K Reich","year":"2015","unstructured":"Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, et al. Evidence that a neutrophil\u2013keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24:529\u201335.","journal-title":"Exp Dermatol."},{"key":"162_CR17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338.","journal-title":"N Engl J Med."},{"key":"162_CR18","volume-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai T-F, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Dermatol: J Am Acad; 2015."},{"issue":"27\u201336","key":"162_CR19","first-page":"e1","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(27\u201336):e1.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"162_CR20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjd.13814","volume":"173","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777\u201387.","journal-title":"Br J Dermatol."},{"key":"162_CR21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484\u201393.","journal-title":"Br J Dermatol."},{"issue":"6","key":"162_CR22","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour J-P, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol JEADV. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"162_CR23","unstructured":"Cosentyx.pdf [Internet]. Available from: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/cosentyx.pdf . Cited 30 May 2015."},{"key":"162_CR24","doi-asserted-by":"crossref","unstructured":"Ward NL, Guettner A, Sands B, Cooper S. Secukinumab safety and tolerability in subjects with moderate to severe plaque psoriasis: a pooled subgroup analysis of 10 clinical studies evaluating exacerbation of Crohn\u2019s disease. J Am Acad Dermatol. 2014;70:AB188.","DOI":"10.1016\/j.jaad.2014.01.778"},{"key":"162_CR25","unstructured":"Blauvelt A. Candidiasis in secukinumab-treated subjects is non-serious and transient: a pooled analysis of data from 10 phase 2 and 3 clinical trials in psoriasis. Chicago, IL; 2014."},{"key":"162_CR26","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Lebwohl MG, Bissonnette R. IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. [Internet]. 2015. Available from: http:\/\/www.nature.com.ezproxy3.lhl.uab.edu\/jid\/journal\/vaop\/ncurrent\/full\/jid2015144a.html . Cited 12 Jul 2015.","DOI":"10.1038\/jid.2015.144"},{"key":"162_CR27","unstructured":"Secukinumab (AIN457) Advisory Committee Briefing Material: Available For Public Release. Prepared by Novartis Pharmaceuticals Co [Internet]. Available from: http:\/\/webcache.googleusercontent.com\/search?q=cache:O9TwOW7TnMkJ:www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DermatologicandOphthalmicDrugsAdvisoryCommittee\/UCM419023.pdf+&cd=1&hl=en&ct=clnk&gl=us . Cited 1 May 2015."},{"key":"162_CR28","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190\u20139.","journal-title":"N Engl J Med."},{"issue":"9","key":"162_CR29","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","volume":"29","author":"RG Langley","year":"2015","unstructured":"Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. JEADV. 2015;29(9):1763\u201370.","journal-title":"J Eur Acad Dermatol Venereol. JEADV."},{"key":"162_CR30","unstructured":"Lilly\u2019s ixekizumab superior to etanercept and placebo in phase 3 psoriasis studies (NYSE:LLY) [Internet]. Available from: https:\/\/investor.lilly.com\/releasedetail.cfm?releaseid=867193 . Cited 30 Jun 2015."},{"issue":"9993","key":"162_CR31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet."},{"key":"162_CR32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.12773","volume":"29","author":"H Saeki","year":"2015","unstructured":"Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz P-Y, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1148\u201355.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"162_CR33","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaad.2014.07.048","volume":"71","author":"KB Gordon","year":"2014","unstructured":"Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71:1176\u201382.","journal-title":"J Am Acad Dermatol."},{"key":"162_CR34","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318\u201328.","journal-title":"N Engl J Med."},{"key":"162_CR35","unstructured":"Amgen. Media\u2014news release [Internet]. Available from: http:\/\/www.amgen.com\/media\/media_pr_detail.jsp?releaseID=1929460 . Cited 1 May 2015."},{"issue":"1183\u201390","key":"162_CR36","first-page":"e3","volume":"71","author":"K Papp","year":"2014","unstructured":"Papp K, Leonardi C, Menter A, Thompson EHZ, Milmont CE, Kricorian G, et al. Safety and efficacy of brodalumab for psoriasis after 120\u00a0weeks of treatment. J Am Acad Dermatol. 2014;71(1183\u201390):e3.","journal-title":"J Am Acad Dermatol."},{"key":"162_CR37","first-page":"891","volume":"146","author":"SK Kurd","year":"2010","unstructured":"Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891\u20135.","journal-title":"Arch Dermatol."},{"key":"162_CR38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2288-11-32","volume":"11","author":"S Langham","year":"2011","unstructured":"Langham S, Langham J, Goertz H-P, Ratcliffe M. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical review. BMC Med Res Methodol. 2011;11:32.","journal-title":"BMC Med Res Methodol."},{"key":"162_CR39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40257-013-0032-x","volume":"14","author":"W-H Boehncke","year":"2013","unstructured":"Boehncke W-H, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14:377\u201388.","journal-title":"Am J Clin Dermatol."},{"key":"162_CR40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133\u201342.","journal-title":"Immunology."},{"key":"162_CR41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2340\/00015555-1833","volume":"94","author":"K Vlam de","year":"2014","unstructured":"de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94:627\u201334.","journal-title":"Acta Derm Venereol."},{"key":"162_CR42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27:127\u201333.","journal-title":"Curr Opin Rheumatol."},{"key":"162_CR43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75:329\u201338.","journal-title":"Drugs."},{"key":"162_CR44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73:349\u201356.","journal-title":"Ann Rheum Dis."},{"key":"162_CR45","doi-asserted-by":"crossref","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet [Internet]. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673615611345 . Cited 12 Jul 2015.","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"162_CR46","unstructured":"Mease PJ, McInnes IB, Kavanaugh A, van der Heijde D. Secukinumab, a human anti\u2013interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study [Internet]. ACR Abstr. Available from: http:\/\/acrabstracts.org\/abstracts\/secukinumab-a-human-anti-interleukin-17a-monoclonal-antibody-improves-active-psoriatic-arthritis-and-inhibits-radiographic-progression-efficacy-and-safety-data-from-a-phase-3-randomize\/ . Cited 12 Jul 2015."},{"key":"162_CR47","unstructured":"Lilly\u2019s ixekizumab met primary endpoint in a phase 3 study investigating the treatment of psoriatic arthritis\u2014Apr 20, 2015 [Internet]. Available from: http:\/\/lilly.mediaroom.com\/index.php?s=9042&item=137406 . Cited 16 May 2015."},{"key":"162_CR48","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","volume":"370","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370:2295\u2013306.","journal-title":"N Engl J Med."},{"key":"162_CR49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1172\/JCI117308","volume":"94","author":"FO Nestle","year":"1994","unstructured":"Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest. 1994;94:202\u20139.","journal-title":"J Clin Invest."},{"key":"162_CR50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","volume":"102","author":"JF Schlaak","year":"1994","unstructured":"Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102:145\u20139.","journal-title":"J Invest Dermatol."},{"key":"162_CR51","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"LM Austin","year":"1999","unstructured":"Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752\u20139.","journal-title":"J Invest Dermatol."},{"key":"162_CR52","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","volume":"6","author":"H Park","year":"2005","unstructured":"Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133\u201341.","journal-title":"Nat Immunol."},{"key":"162_CR53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123\u201332.","journal-title":"Nat Immunol."},{"key":"162_CR54","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","volume":"129","author":"A Cesare Di","year":"2009","unstructured":"Di Cesare A, Di Meglio P, Nestle FO. The IL-23\/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339\u201350.","journal-title":"J Invest Dermatol."},{"key":"162_CR55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaad.2013.10.043","volume":"70","author":"AA Levin","year":"2014","unstructured":"Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70:555\u201361.","journal-title":"J Am Acad Dermatol."},{"key":"162_CR56","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123\u201332.","journal-title":"Nat Immunol."},{"key":"162_CR57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.smim.2007.10.007","volume":"19","author":"T Korn","year":"2007","unstructured":"Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19:362\u201371.","journal-title":"Semin Immunol."},{"key":"162_CR58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.immunol.22.012703.104758","volume":"25","author":"RA Kastelein","year":"2007","unstructured":"Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221\u201342.","journal-title":"Annu Rev Immunol."},{"key":"162_CR59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585\u2013600.","journal-title":"Nat Rev Immunol."},{"key":"162_CR60","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","volume":"128","author":"C Koga","year":"2008","unstructured":"Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625\u201330.","journal-title":"J Invest Dermatol."},{"key":"162_CR61","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556\u201367.","journal-title":"Nat Rev Immunol."},{"issue":"187","key":"162_CR62","first-page":"490","volume":"2011","author":"AM Lin","year":"1950","unstructured":"Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol Baltim Md. 1950;2011(187):490\u2013500.","journal-title":"J Immunol Baltim Md"},{"key":"162_CR63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","volume":"133","author":"DA Martin","year":"2013","unstructured":"Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17\u201326.","journal-title":"J Invest Dermatol."},{"key":"162_CR64","doi-asserted-by":"crossref","first-page":"e90284","DOI":"10.1371\/journal.pone.0090284","volume":"9","author":"A Chiricozzi","year":"2014","unstructured":"Chiricozzi A, Nograles KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM, et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PloS One. 2014;9:e90284.","journal-title":"PloS One."},{"key":"162_CR65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","volume":"359","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359:419\u201329.","journal-title":"Mol Cell Biochem."},{"key":"162_CR66","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","volume":"58","author":"C Jandus","year":"2008","unstructured":"Jandus C, Bioley G, Rivals J-P, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307\u201317.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"162_CR67","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","volume":"122","author":"E Letko","year":"2015","unstructured":"Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939\u201348.","journal-title":"Ophthalmology."},{"key":"162_CR68","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777\u201387.","journal-title":"Ophthalmology."},{"key":"162_CR69","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3899\/jrheum.130637","volume":"41","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014;41:414\u201321.","journal-title":"J Rheumatol."},{"key":"162_CR70","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72:863\u20139.","journal-title":"Ann Rheum Dis."},{"key":"162_CR71","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","volume":"66","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Greenwald M, Cho C-S, Berman A, Jin L, Cameron GS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol Hoboken NJ. 2014;66:1693\u2013704.","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"key":"162_CR72","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar4347","volume":"15","author":"DA Martin","year":"2013","unstructured":"Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, Wallace D, Martin R, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013;15:R164.","journal-title":"Arthritis Res Ther"},{"key":"162_CR73","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313.","journal-title":"Lancet."},{"key":"162_CR74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cyto.2013.03.013","volume":"62","author":"JB Golden","year":"2013","unstructured":"Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013;62:195\u2013201.","journal-title":"Cytokine."},{"key":"162_CR75","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/STROKEAHA.114.006516","volume":"46","author":"A Abbas","year":"2015","unstructured":"Abbas A, Gregersen I, Holm S, Daissormont I, Bjerkeli V, Krohg-S\u00f8rensen K, et al. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23\/interleukin 17 axis. Stroke J Cereb Circ. 2015;46:793\u20139.","journal-title":"Stroke J Cereb Circ."},{"key":"162_CR76","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/jid.2012.112","volume":"132","author":"Y Wang","year":"2012","unstructured":"Wang Y, Gao H, Loyd CM, Fu W, Diaconu D, Liu S, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012;132:2067\u201375.","journal-title":"J Invest Dermatol."},{"key":"162_CR77","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/eji.201445052","volume":"45","author":"L Nardinocchi","year":"2015","unstructured":"Nardinocchi L, Sonego G, Passarelli F, Avitabile S, Scarponi C, Failla CM, et al. Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol. 2015;45:922\u201331.","journal-title":"Eur J Immunol."},{"issue":"2","key":"162_CR78","first-page":"e32126","volume":"7","author":"D He","year":"2012","unstructured":"He D, Li H, Yusuf N, Elmets C, Athar M, Katiyar S, et al. IL-17 receptor A deficient mice are resistant to chemical carcinogen induced cutaneous tumors. J Invest Dermatol. 2012;7(2):e32126.","journal-title":"J Invest Dermatol."},{"key":"162_CR79","doi-asserted-by":"crossref","first-page":"e32126","DOI":"10.1371\/journal.pone.0032126","volume":"7","author":"D He","year":"2012","unstructured":"He D, Li H, Yusuf N, Elmets CA, Athar M, Katiyar SK, et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PloS One. 2012;7:e32126.","journal-title":"PloS One."},{"issue":"184","key":"162_CR80","first-page":"2281","volume":"2010","author":"D He","year":"1950","unstructured":"He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol Baltim Md. 1950;2010(184):2281\u20138.","journal-title":"J Immunol Baltim Md"},{"key":"162_CR81","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1756-185X.2011.01673.x","volume":"15","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ho RC-M, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis. 2012;15:183\u20137.","journal-title":"Int J Rheum Dis."},{"key":"162_CR82","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4306\/pi.2013.10.3.294","volume":"10","author":"J-W Kim","year":"2013","unstructured":"Kim J-W, Kim Y-K, Hwang J-A, Yoon H-K, Ko Y-H, Han C, et al. Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder. Psychiatry Investig. 2013;10:294\u20139.","journal-title":"Psychiatry Investig."},{"key":"162_CR83","unstructured":"Amgen\u2014Media-news release [Internet]. Available from: http:\/\/www.amgen.com\/media\/media_pr_detail.jsp?year=2015&releaseID=2052862 . Cited 30 May 2015."},{"key":"162_CR84","unstructured":"AstraZeneca\u2014AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab [Internet]. Available from: http:\/\/www.astrazeneca.com\/Media\/Press-releases\/Article\/20150901\u2013astrazeneca-and-valeant-pharmaceuticals-partnership . Cited 8 Sep 2015."},{"key":"162_CR85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WYK Hwang","year":"2005","unstructured":"Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods San Diego Calif. 2005;36:3\u201310.","journal-title":"Methods San Diego Calif."},{"key":"162_CR86","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cellsig.2010.11.022","volume":"23","author":"SH Chang","year":"2011","unstructured":"Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal. 2011;23:1069\u201375.","journal-title":"Cell Signal."},{"key":"162_CR87","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1084\/jem.20061675","volume":"204","author":"P Angkasekwinai","year":"2007","unstructured":"Angkasekwinai P, Park H, Wang Y-H, Wang Y-H, Chang SH, Corry DB, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med. 2007;204:1509\u201317.","journal-title":"J Exp Med."},{"key":"162_CR88","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1084\/jem.20051615","volume":"203","author":"PG Fallon","year":"2006","unstructured":"Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med. 2006;203:1105\u201316.","journal-title":"J Exp Med."},{"key":"162_CR89","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2133.2007.07817.x","volume":"156","author":"RP Katugampola","year":"2007","unstructured":"Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945\u201350.","journal-title":"Br J Dermatol."},{"key":"162_CR90","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000113150","volume":"216","author":"DA Revicki","year":"2008","unstructured":"Revicki DA, Willian MK, Menter A, Saurat J-H, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatol Basel Switz. 2008;216:260\u201370.","journal-title":"Dermatol Basel Switz."},{"key":"162_CR91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1346-8138.2011.01459.x","volume":"39","author":"H Torii","year":"2012","unstructured":"Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese Infliximab Study Investigators. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39:253\u20139.","journal-title":"J Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-015-0162-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0162-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T19:11:53Z","timestamp":1653765113000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-015-0162-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1007\/s40257-015-0162-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]}}}